EXOZ

4 - EXOZYMES INC. (0002010788) (Issuer)

4 - EXOZYMES INC. (0002010788) (Issuer)

Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments.Michael Heltzen, CEO of eXoZymes, states, "We have taken a molecule from concept to pilot validation and now beyond our original commercial economic targets in less than two years. That speed is exactly what I believe can make eXoZymes comm

Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.The new process produced approximately 67% more NCT per liter than the previously announced 100-liter pilot run.Reaction time was reduced by over 80%, allowing substantially more product to be produced in less time.The improvements support a more scalable and efficient manufacturing process as eXoZymes prepares for technology transfer to future commercial p

Addison, TX, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-defining, disruptive technology companies, provides a business update for the quarter ended June 30, 2026, and subsequent developments. First Six Months of 2026 and Subsequent Operational Highlights Completed $20 million IPO for Buda Juice (NYSE:BUDA) as the sole bookrunner and underwriter, our 18th consecutive successful IPO. Partnered with Roth Capital Partners and Bancroft Capital as joint bookrunners for the $15 million Ticketplus IPO (NYSE American; TP).Completed underwriting of $5.9 million public offering for eXoZymes (NASDAQ:EXO

10-Q - EXOZYMES INC. (0002010788) (Filer)

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call. LOS ANGELES, CA / ACCESS Newswire / August 11, 2026 / CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.Investors can pre-register

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymesExpands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.Provides access to the DOE Genesis Mission Platform, including advanced AI models, AI agents and high-performance computing infrastructure to accelerate future platform development. LOS ANGELES, CA / ACCESS Newswire / July 23, 2026 / Tod

8-K - EXOZYMES INC. (0002010788) (Filer)

424B5 - EXOZYMES INC. (0002010788) (Filer)

8-K - EXOZYMES INC. (0002010788) (Filer)

Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules.NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partnership and commercialization.Total non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company's platform LOS ANGELES, CA / ACCESS Newswire / June 24, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) - a pioneer of AI-enhanced enzymes that enable scalable manufactur

8-K - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants.The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common stock and one warrant to purchase one additional share of common stock. The public offering price per share was $8.99 and per warrant was $0.02 resulting in gross proceeds of approximately $5.95 million

8-K - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant.The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance and all shares of common stock and warrants that comprise the units are being is

424B5 - EXOZYMES INC. (0002010788) (Filer)

424B5 - EXOZYMES INC. (0002010788) (Filer)

424B5 - EXOZYMES INC. (0002010788) (Filer)

10-Q - EXOZYMES INC. (0002010788) (Filer)

LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medicines, and valuable chemicals - announced its graduation from the Shell GameChanger™ Accelerator, a multimillion-dollar, multiyear program developed in collaboration between Shell and the U.S. Department of Energy's National Laboratory of the Rockies (NLR).From 2023 to 2026, eXoZymes partnered with GCxN to advance the next generation of transformative technologies with the potential to dramatically alter the future global energy landscape. The collaboration helped advance eXoZymes' cell-free bioma

8-K - EXOZYMES INC. (0002010788) (Filer)

8-K - EXOZYMES INC. (0002010788) (Filer)

4 - EXOZYMES INC. (0002010788) (Issuer)

LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Commercial Officer, Damien Perriman was featured on the latest episode of the industry leading Grow Everything podcast to discuss the company's first spinout, NCTx, and how eXoZymes is building a repeatable commercialization model for high-value natural products.The Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder. Previous episodes have featured guests - including key individuals from companies like NVIDIA, P&